Related Experiment Video
Updated: May 10, 2026
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
The next therapeutic challenge in HIV: polypharmacy
E Jennifer Edelman1, Kirsha S Gordon, Janis Glover
1Yale University School of Medicine, New Haven, CT, USA. ejennifer.edelman@yale.edu
Drugs & Aging
|June 7, 2013
Summary
Polypharmacy, using multiple medications, poses risks for people with HIV (PLWH) due to increased medication interactions, adverse events, and frailty. This study proposes a framework to manage polypharmacy in lifelong combination antiretroviral therapy (ART).
Area of Science:
- Geriatrics
- Infectious Diseases
- Pharmacology
Background:
- Combination antiretroviral therapy (ART) is standard for HIV, often leading to polypharmacy (≥5 medications).
- Polypharmacy increases risks of nonadherence, adverse drug events, organ injury, hospitalization, geriatric syndromes, and mortality in people with HIV (PLWH).
- Existing polypharmacy literature needs adaptation for PLWH due to lifelong ART, higher comorbidity risk, and enhanced susceptibility to harm.
Purpose of the Study:
- To review the literature on polypharmacy in PLWH on chronic ART.
- To propose an adapted framework for managing polypharmacy in this population.
- To identify future research directions for addressing polypharmacy in PLWH.
Main Methods:
- Literature review of polypharmacy in HIV and non-HIV populations.
- Adaptation of existing polypharmacy frameworks for the unique context of lifelong ART.
- Identification of specific challenges and considerations for PLWH.
Main Results:
- Polypharmacy is a significant concern for PLWH, with risks amplified by age, frailty, and HIV-specific factors.
- Lifelong ART necessitates tailored approaches to polypharmacy management.
- PLWH may have increased vulnerability to polypharmacy harms due to chronic inflammation and immune dysfunction.
Conclusions:
- An adapted framework is proposed to address polypharmacy challenges in individuals on lifelong ART.
- Further research is needed to optimize polypharmacy management strategies for PLWH.
- Addressing polypharmacy is crucial for improving health outcomes and quality of life for aging PLWH.
More Related Videos
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...